![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-desktop-header-01gif-33629.gif)
![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-mob-header-01gif-17728.gif)
20
Glaxosmithkline Research & Development Limited Brentford Gb, based in United Kingdom, is a pharmaceutical company that stands out with its certifications from FDA, EDQM and WHO-GMP.
One of their significant offerings is Mupirocin calcium, supported by a 'Withdrawn by Holder' Certificate of Suitability (CEP) with the number R1-CEP 2011-048 - Rev 00
This Chemical Type CEP, issued on June 02, 2017, remains in force until December 01, 2020, ensuring its reliability within the pharmaceutical industry.
Substance Number 1451 associated with this CEP further emphasizes